Observations from ID and Beyond: After the PANORAMIC Study — Whither Molnupiravir?

In HIV and ID Observations, Dr. Paul Sax addresses a second controversial COVID-19 paper published in late 2022.

In the second of three posts addressing some recent COVID-19–related papers that led to debates among ID specialists, Dr. Paul Sax takes a deep dive into a study on open-label molnupiravir versus usual care. See the critical view of treatment with molnupiravir, the supportive view, and Dr. Sax's take, in the latest HIV and ID Observations.

Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.

Want to see more from NEJM Journal Watch? Register here.

Observations from ID and Beyond: After the PANORAMIC Study — Whither Molnupiravir?

Topics